华泰柏瑞恒生生物科技交易型开放式指数证券投资基金基金合同及招募说明书提示性公告

Core Viewpoint - The announcement pertains to the disclosure of the full text of the fund contract and the prospectus for the Huatai-PB Hang Seng Biotechnology Exchange-Traded Open-Ended Index Securities Investment Fund, which will be available for investor review on February 4, 2026 [1] Group 1 - The fund management company commits to managing and utilizing fund assets with principles of honesty, credit, diligence, and responsibility [1] - There is no guarantee of profit or minimum returns from the fund, emphasizing the importance of understanding the risk-return characteristics before making investment decisions [1]